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Abstract
 
The immunosurveillance of transformed cells by the immune system remains one of the most
controversial and poorly understood areas of immunity. Gene-targeted mice have greatly aided
our understanding of the key effector molecules in tumor immunity. Herein, we describe
spontaneous tumor development in gene-targeted mice lacking interferon (IFN)-
 
 
 
 and/or per-
forin (pfp), or the immunoregulatory cytokines, interleukin (IL)-12, IL-18, and tumor necrosis
factor (TNF). Both IFN-
 
 
 
 and pfp were critical for suppression of lymphomagenesis, however
the level of protection afforded by IFN-
 
 
 
 was strain specific. Lymphomas arising in IFN-
 
 
 
-
deficient mice were very nonimmunogenic compared with those derived from pfp-deficient
mice, suggesting a comparatively weaker immunoselection pressure by IFN-
 
 
 
. Single loss of
IL-12, IL-18, or TNF was not sufficient for spontaneous tumor development. A significant in-
cidence of late onset adenocarcinoma observed in both IFN-
 
 
 
– and pfp-deficient mice indi-
cated that some epithelial tissues were also subject to immunosurveillance.
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Introduction
 
Although tumor immunosurveillance was first hypothe-
sized more than four decades ago, the observed absence
of spontaneous tumors in several immune-compromised
mouse strains initially dampened enthusiasm for this idea.
mAbs specific for immunoregulators have sometimes proven
useful in establishing the importance of such molecules in
immunity against experimental tumors (1–3). Production
of gene-targeted mice for specific effector molecules has
greatly aided this endeavor (4–14). Nevertheless, experi-
mental tumor models examined to date have provided lim-
ited information on tumor initiation and development.
IFN-
 
 
 
 (15) and perforin (pfp; references 5, 14, and 16), key
molecules of both the innate and adaptive immune systems,
contribute to tumor prevention in mice treated with the
chemical carcinogen, methylcholanthrene (MCA), or in mice
deficient for p53 expression. In MCA- (10) and other car-
cinogen-induced cutaneous malignancy models (17), the
importance of antitumor immunity mediated by NK cells,
NK T cells, and 
 
  
 
  
 
T cells has also been illustrated. How-
ever, in most of these models tumor development involves
the transformation of many cells at one time and only a de-
fined spectrum of tumors (lymphomas and cutaneous ma-
lignancies) is observed. An alternative model of tumor in-
duction is that spontaneous tumors can arise from a single
cell of any tissue that has acquired the appropriate genetic
mutations with age in any given environment. Herein, that
environment has been controlled, and spontaneous tumor
initiation compared in WT and gene-targeted mice of the
same genetic background to illustrate the key role pfp and
IFN-
 
 
 
 play in tumor immunosurveillance of lymphoma
and lung adenocarcinoma.
 
Materials and Methods
 
Mice.
 
Inbred C57BL/6J and BALB/c WT mice were pur-
chased from The Walter and Eliza Hall Institute of Medical Re-
search, Melbourne, Australia. The following gene-targeted mice
were bred and maintained at the Austin Research Institute Bio-
logical Research Laboratories, Heidelberg, Australia and the Pe-
ter MacCallum Cancer Institute, East Melbourne, Australia:
C57BL/6J pfp-deficient (B6 pfp
 
 
 
/
 
 
 
) (targeted in C57BL/6J ES
cells and provided by D. Kagi [Amgen Institute, Toronto, Can-
ada]; reference 18); C57BL/6J TNF-deficient (B6 TNF
 
 
 
/
 
 
 
) (tar-
geted in C57BL/6J ES cells [reference 19] and provided by Dr.
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J.D. Sedgwick and originally from the Centenary Institute of
Cancer Medicine and Cell Biology, Sydney, Australia); C57BL/6
IFN-
 
 
 
-deficient (B6 IFN-
 
 
 
 
 
/
 
 
 
)(backcrossed to C57BL/6J for 10
generations from Genentech, Inc.; reference 20); C57BL/6 IL-
12p40-deficient (B6 IL-12
 
 
 
/
 
 
 
)(backcrossed to C57BL/6J for 10
generations from Hoffmann-La Roche; reference 21); C57BL/6
IL-18–deficient (B6 IL-18
 
 
 
/
 
 
 
) (backcrossed to C57BL/6J for
eight generations and provided by Dr. S. Akira, Osaka Univer-
sity, Japan; reference 22); BALB/c pfp
 
 
 
/
 
 
 
 (backcrossed to
BALB/c for eight generations using microsatellite mapping),
BALB/c IFN-
 
 
 
 
 
/
 
 
 
 (backcrossed to BALB/c for 10 generations
from Genentech, Inc., reference 20); and BALB/c pfp
 
 
 
/
 
 
 
 IFN-
 
 
 
 
 
/
 
 
 
. F1 heterozygote progeny of some gene-targeted mice and
their corresponding WT were bred as follows: (B6 
 
  
 
B6 IFN-
 
 
 
 
 
/
 
 
 
)F1; (BALB/c 
 
  
 
BALB/c IFN-
 
 
 
 
 
/
 
 
 
)F1; and (BALB/c 
 
 
 
BALB/c pfp
 
 
 
/
 
 
 
)F1. All aging mice were routinely screened for
viruses, parasites, and other microbes and tested negative over the
entire course of the experiment. Mice within the study were
monitored for health and weighed twice weekly. Any mouse
with an abnormality (palpable mass, abdominal distension, weight
loss 
 
 
 
10%, ruffled fur) was killed, its age recorded, and a post-
mortem performed. Mean lifespan 
 
  
 
SEM was calculated and
probability of significance determined using a Mann-Whitney
Rank Sum U-test. The significance of proportions of tumors and,
in particular, disseminated lymphomas, was determined by a
Fisher’s exact test.
 
Histopathology and Surface Phenotyping of Tumors.
 
A full au-
topsy was performed at sacrifice and tumor (macroscopically de-
tected), spleen, liver, thymus, and lymph nodes were routinely
examined by histology after fixing these tissues in formalin and on
occasions also fresh frozen. The preparation and staining of sec-
tions for histology were performed by the Department of Ana-
tomical Pathology, Austin and Repatriation Medical Centre,
Heidelberg, Australia. Lymphomas from mice were also assessed
for surface phenotype by multiparameter flow cytometric analysis.
The following reagents were used: anti–
 
   
 
TCR-APC (H57–
597; BD PharMingen); NK1.1-PE (PK136; BD PharMingen);
CD4-FITC (CT4; Caltag Laboratories); CD8
 
 
 
-APC (53.6.7; BD
PharMingen); CD8
 
 
 
-biotin (53.5.8; BD PharMingen); CD11c-
FITC (HL3; BD PharMingen); B220-PE (RA3–6B2; Caltag
Laboratories); Thy-1-PE (30-H12; BD PharMingen); CD45.2-
FITC (104; BD PharMingen); 
 
   
 
TCR-biotin (clone GL3; BD
PharMingen); Mac-1-biotin (M170; Caltag Laboratories); goat
anti–mouse Ig-FITC (Silenus Laboratories); and streptavidin-
PerCP (BD PharMingen). Anti-Fc receptor (2.4G2) was used to
prevent nonspecific binding by mAb. Staining was performed in
PBS with 5% FCS and 0.02% sodium azide on ice. Fresh spleno-
cytes from 6-wk-old B6 or BALB/c mice were always used as la-
beling controls. Analysis was performed on a FACScalibur™ us-
ing CELLQuest™ software (Becton Dickinson).
 
Tumor Transplantation Experiments.
 
A number of disseminated
lymphomas were transplanted directly from B6.pfp
 
 
 
/
 
 
 
, BALB/c
pfp
 
 
 
/
 
 
 
, or B6 IFN-
 
 
 
 
 
/
 
 
 
mice into WT mice or mice of the same
genotype. Two representative experiments are shown using a B
cell lymphoma from B6.pfp
 
 
 
/
 
 
 
 mice, PNK7 (B220
 
 
 
Ig
 
 
 
TCR-
 
  
 
 
 
), and a T cell lymphoma from B6 IFN-
 
 
 
 
 
/
 
 
 
 mice, BG18
(CD8-
 
  
 
 
 
CD4
 
  
 
TCR-
 
  
 
 
 
Ig
 
 
 
). Groups of five WT or gene-
targeted mice were injected intraperitoneally with increasing
numbers of lymphoma cells and observed daily for tumor growth
for 
 
 
 
100 d.
 
Online Supplemental Materials.
 
The supplemental figures are a
(Fig. S1) histology of spontaneous neoplasia in immunodeficient
mice and a (Fig. S2) flow cytometric analysis of lymphomas aris-
 
ing in BALB pfp
 
 
 
/
 
 
 
 and B6 pfp
 
 
 
/
 
 
 
 mice. These can be found
at http://www.jem.org/cgi/content/full/jem.20020063/DC1 or
from the authors by request.
 
Results and Discussion
 
We undertook to monitor spontaneous tumor develop-
ment in WT C57BL/6 (B6) and BALB/c mice or those
that were deficient in IFN-
 
 
 
 and/or pfp. B6 mice deficient
in IL-12, IL-18, or TNF were also examined, as all of these
cytokines have been shown to regulate the expression of
IFN-
 
 
 
 and other effector molecules in lymphocytes (23–
27). B6 IFN-
 
 
 
 
 
/
 
 
 
 mice developed disseminated lympho-
mas (16/32 (50%) and mean lifespan 491 
 
 
 
 104 d) (Fig. 1
A). A few mice developed thymic lymphomas (
 
n
 
   
 
2) or
sarcoma (
 
n
 
   
 
1). Like WT B6 mice (0/39 mice), B6 mice
that were deficient in TNF (0/36), IL-12 (0/29), or IL-18
(0/27) did not develop any tumors over the same observa-
tion period (Fig. 1 A). These data illustrate spontaneous
lymphoma formation in IFN-
 
 
 
–deficient mice and suggest
that more than one of the upstream mediators of IFN-
 
 
 
 or
an alternative cytokine must be required to regulate the
Figure 1. Pfp and IFN-  protect mice from spontaneous lymphoma.
The appearance of tumors was recorded in mice of (A) C57BL/6 and (B)
BALB/c backgrounds as indicated. Groups of mice (number in parenthe-
ses) were evaluated on a weekly basis and, when moribund, tumor type
(white squares, thymic lymphoma; black squares, disseminated lym-
phoma; black triangles, sarcoma; white triangles, lung adenocarcinoma;
and white circles, other tumors) recorded against the age at the time of
death/autopsy (in days). *, disseminated lymphomas of histiocyte mor-
phology. No tumors were observed in heterozygote control groups of
(B6   B6 IFN-  / )F1(n   17), (BALB/c   BALB/c IFN-  / )F1 (n  
12), and (BALB/c   BALB/c pfp / )F1 (n   18) mice over a 750-d pe-
riod. A small number of the oldest surviving BALB/c IFN-  /  mice (700–
750 d) also developed nonmalignant mucosal hamartomas in the stomach. 
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protective effects of IFN-
 
 
 
. Consistent with our previous
study (16), B6 pfp
 
 
 
/
 
 
 
 mice died from aggressive dissemi-
nated lymphomas affecting the spleen, liver, and lymph
nodes from 300 d onwards, with 57% (12/21) succumbing
by the end of the experiment (mean lifespan 
 
 
 
 510 
 
 
 
 119 d;
Fig. 1 A).
Of great interest was a considerably distinct pattern of
tumor development observed in similar gene-targeted mice
on a BALB/c background (Fig. 1 B). In striking contrast to
B6 IFN-
 
 
 
 
 
/
 
 
 
 mice, BALB/c IFN-
 
 
 
 
 
/
 
 
 
 mice did not de-
velop disseminated lymphoma (0/19, 
 
P
 
 
 
 
 
 0.0001). The
finding that IFN-
 
 
 
 was not essential for host protection
from this type of tumor in BALB/c mice illustrated that
strain-specific genetic factors can influence the nature of
the immune response to these spontaneous lymphomas. By
contrast, pfp was critical in host protection from dissemi-
nated lymphoma in both strains (Fig. 1 A versus Fig. 1 B).
9 of 25 BALB/c pfp
 
 
 
/
 
 
 
 mice developed disseminated lym-
phoma (mean lifespan 
 
 
 
 597   82 d), and a few mice de-
veloped thymic lymphomas (n   2) or sarcoma (n   1; Fig.
1 B). The earlier onset (mean lifespan   368   120 d) (P  
0.0001, compared with pfp /  mice) and greater frequency
(14/20) of disseminated lymphoma in BALB/c mice defi-
cient in both pfp and IFN- , revealed that in the absence
of pfp, IFN-  did play an important role in delaying the
development of disseminated lymphoma (Fig. 1 B). These
data supported a general role for IFN-  in protection from
spontaneous lymphoma, but suggested that the relative role
of IFN-  was strain specific.
Lymphocyte-mediated immunosurveillance of epithelial
malignancy has never been demonstrated, except where vi-
ral infection may contribute to oncogenesis (e.g., EBV,
HPV transplant recipients) or when carcinogens were also
administered, and we therefore felt the development of
spontaneous epithelial tumors in gene-targeted mice war-
ranted particular attention. While IFN-  and pfp were es-
pecially important for the control of disseminated lym-
phoma, a significant incidence of lung adenocarcinoma was
detected in BALB/c IFN-  /  mice (3/19, P   0.0269)
and BALB/c pfp /  mice (3/25, P   0.048) (Fig. 1). These
data directly demonstrated that IFN-  and pfp suppressed
some epithelial malignancies. Notably, it is relevant that the
onset of lung adenocarcinomas was very late in BALB/c
IFN-  /  (681   43 d) and BALB/c pfp /  (693   67 d)
mice. Indeed, the development of all tumors, including dis-
seminated lymphomas was significantly delayed in BALB/c
mice compared with B6 mice. Far fewer BALB/c pfp / 
IFN-  / , B6 IFN-  / , and B6 pfp /  mice remained
alive (free of lymphoma) over the first 600 d of life and
therefore larger numbers of these will likely be required to
observe adenocarcinomas. F1 progeny of gene-null mice
and WT mice lacking either one allele of pfp or IFN-  did
not develop any spontaneous tumors (Fig. 1). Determining
whether the immune system controls other epithelial ma-
lignancies is an important issue for future long-term studies
and only a similar study of far larger groups of mice ( 100)
will reveal whether significant numbers of other epithelial
malignancies emerge in IFN-  /  and pfp /  mice.
6 of the 16 lymphomas arising in B6 IFN-  /  mice
were analyzed for phenotype and while five were TCR-
   , no unique lymphoma phenotype was apparent (un-
published data). Several previous studies have indicated that
T cell death after antigen-driven expansion may be regu-
lated by IFN-  (28, 29), and therefore possibly disrupted
homeostasis and failed immunosurveillance by IFN-  loss,
may be the cause of T cell lymphoma in B6 IFN-  / 
mice. All of the disseminated lymphomas in B6 pfp / 
mice were of B cell origin (B220  sIg  CD4 CD8 
TCR ), or plasmacytomas (B220  CD4  CD8  TCR 
sIglow; also defined histologically, unpublished data). Our
previous study of pfp /  mice with additional p53 loss in-
dicated a majority of lymphomas of B cell origin, however
some p53 / pfp /  mice also developed lymphomas of
non-B cell origin (16). One explanation for the develop-
ment of B cell lymphomas in pfp /  mice is the recognized
role for pfp in controlling the survival of some APCs, like
B cells (30, 31). However, it remains unclear why only
lymphomas of B cell origin developed in B6 pfp /  mice
when enhanced expansions of CD8  T cells were observed
in these mice, particularly after challenge with foreign anti-
gens (e.g., viral or bacterial infection; references 28, and
32–34). Most of the lymphomas in B6 pfp /  and B6 IFN-
  /  mice were diffuse large cell lymphomas (see Online
Supplemental Materials).
Flow cytometric analysis of disseminated lymphomas in
BALB/c pfp /  and BALB/c pfp / IFN-  /  mice re-
vealed that all were also B220  sIg  CD4 CD8  TCR 
(unpublished data). Importantly, these data supported a role
for IFN-  in also suppressing the earlier onset of B cell
lymphomas. Interestingly, in the BALB/c strain, a small
number of the lymphomas arising in pfp /  and pfp / 
IFN-  /  mice showed an unusual histiocytic appearance
(Fig. 1, asterisk) with a pale eosinophilic cytoplasm. These
tumors additionally expressed CD11c and Mac-1 antigens
(see Online Supplemental Materials), but did not all express
other markers of B1 cells (e.g., CD5, unpublished data). Of
note, this type of histopathology occurs only rarely in hu-
mans, and interestingly the accumulations of activated histi-
ocytes (macrophages) observed in pfp-deficient humans
displaying familial hemophagocytic lymphohistiocytosis
(35) are one example. All the lung adenocarcinomas in
both BALB/c pfp /  and BALB/c IFN-  /  mice were
well-differentiated papillary adenocarcinomas (see Online
Supplemental Materials).
The malignancy of primary tumors arising was addi-
tionally confirmed by secondary transfer into mice of the
same strain. Two representative experiments of  10 using
different disseminated lymphomas transferred from either
B6 pfp /  or B6 IFN-  /  mice are depicted in Fig. 2.
The transfer of three different T cell lymphomas from B6
IFN-  /  mice (one shown) demonstrated that these tu-
mors grew at a similar rate in B6 IFN-  /  and B6 WT
mice (Fig. 2). By contrast, and in concert with our previ-
ous data (16), all B cell lymphomas from B6 pfp /  mice
grew at low cell numbers in B6 pfp /  mice, but were av-
idly rejected when transferred into B6 WT mice (Fig. 2).132 Tumor Immunosurveillance Effected by Interferon  
Thus far, all lymphomas of B cell origin arising in pfp / 
mice, including five described herein, were rejected in
WT mice by CD8  T cells (reference 16 and unpublished
data) and in this study the donor tumor cells and recipient
mice were genetically matched as closely as possible. Sim-
ilar experiments with three different B cell lymphomas
from BALB/c pfp /  mice have also demonstrated rejec-
tion in BALB/c WT mice and (BALB/c    BALB/c.
pfp / )F1 heterozygous mice, but not BALB/c pfp /  mice
(unpublished data). In concert with our previous lym-
phoma transfer studies (16), it is likely that the lymphomas
of B cell origin are generally being detected by CD8  T
cells independently of any alloantigens potentially ex-
pressed by the tumor. It is probable that the lack of detect-
able immunogenicity of lymphomas from IFN-  /  mice
indicates an important functional distinction between the
activities of IFN-  and pfp in eliminating potentially
transformed cells. Consistent with the immune system
functioning as a tumor-suppressor system, our results indi-
cated that the immunoselection pressure of pfp on tumor
cells was strong. Lymphomas from pfp-deficient mice
have emerged in the absence of this significant immunose-
lection pressure, and they are avidly rejected in WT mice
upon transfer. Immunoselection by IFN-  appears far
weaker from our spontaneous lymphoma transplant data,
however it has been demonstrated in an experimental sys-
tem using MCA fibrosarcomas arising in IFN-  receptor-
deficient mice (36).
Previous studies have demonstrated that T cells (2), NK
T cells (37), and NK cells (37) can all produce IFN-  with
antitumor activity. It remains unclear which type of lym-
phocytes use IFN-  to control spontaneous lymphomas or
lung adenocarcinomas, and this issue is very difficult to ad-
dress without mice conditionally deficient (e.g., NK cell,
NK T cell, or T cell) in IFN- . Defining exactly how a
pleiotropic cytokine like IFN-  mediates host protection
from spontaneous tumors will also be a challenging goal for
future investigation given that the lymphomas arising in B6
IFN-  /  mice appear nonimmunogenic when transferred
into WT mice. Many potential direct and indirect activities
of IFN-  could suppress spontaneous tumor formation. Al-
though IFN-  can suppress tumor angiogenesis, it is un-
likely that this is the main mode of action in preventing the
development of nonsolid tumors such as disseminated lym-
phomas. It also remains feasible that loss of IFN-  may re-
sult in tumor promotion by another factor normally sup-
pressed by IFN- .
Gene-targeted mice have been extremely valuable when
used in models where tumors are induced by viruses or car-
cinogens or simply when the mice were aged for spontane-
ous tumor formation. The value of using several types of
tumor induction models is no better illustrated by the lack
of tumor development in TNF /  mice, but the reduced
predisposition of these mice to carcinogen-induced skin tu-
mors (38). Although some other recent studies  in aging
mice have suggested that tumor immunosurveillance may
exist (16, 36), our study directly demonstrated the specific
importance of IFN-  in the development of lymphomas
and adenocarcinomas. Recently, a study of aging 129/Sv
mice doubly deficient for recombination activating gene
(RAG)-2 and signal transducer and activator of transcrip-
tion (STAT)-1, the transcription factor mediating signaling
by IFN-  and IFN- /  receptors (RAG-2 / STAT-1 / ),
suggested that lymphocytes and IFN-  may play an im-
portant role in host protection from breast and colon carci-
nomas (36). Mice deficient in STAT-1 alone displayed a
low incidence of mammary carcinoma, however STAT-1
regulates far more genes than IFNs alone, including the
mammary tumor suppressor, BRCA-1 (39). The lack of
lymphoma reported in 129/Sv STAT-1 mice (32) may be
because 129/Sv behave like the BALB/c strain. Neverthe-
less, we did not observe colon or breast adenocarcinomas in
either BALB/c or C57BL/6 strains of IFN- -deficient
mice. The development of mammary and colon adenocar-
cinomas in 129/SvEv RAG-2 / STAT-1 /  mice may be
a consequence of intestinal hyperplasia peculiar to 129
RAG /  mice. By contrast, the lung adenocarcinomas ob-
served in BALB/c pfp /  and BALB/c IFN-  /  mice oc-
curred in strains of mice with no evidence of predisposing
epithelial hyperplasia. The concept of whether lympho-
cytes play a key role in immunosurveillance beyond their
own regulation (i.e., of nonlymphoid tissues) has been de-
bated for years (40). The adenocarcinomas observed in
mice in our study suggested that future studies, monitoring
spontaneous tumor development in gene-targeted mice
alone and bred with other strains genetically prone to epi-
thelial malignancies, will be most informative.
Figure 2. Distinct behavior of lymphomas arising in B6 pfp /  mice
and B6 IFN-  /  mice. Primary lymphomas arising in B6 pfp /  (top)
and B6.IFN-  /  (bottom) were secondarily transplanted intraperito-
neally (101–107 cells in 0.2 ml PBS, as indicated) into groups of five un-
treated B6 WT (black circles or squares), B6 pfp /  (white circles) or B6
IFN-  /  (white squares) mice. Mice were monitored for 100 d and each
symbol depicts an individual mouse. Tumor-free mice are indicated
above the horizontal line. The results are representative of seven primary
lymphomas and three primary lymphomas transplanted from B6 pfp / 
and B6 IFN-  /  mice, respectively. Top, PNK-7 (B cell lymphoma
from B6 pfp /  mouse); bottom, BG18 (T cell lymphoma from B6
IFN-  /  mouse).133 Street et al. Brief Definitive Report
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